A Randomised, Cross-over Study to Evaluate Efficacy and Tolerability of FLX-787 in Patients with Multiple Sclerosis spasticity and spasms/cramps
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Cramp; Multiple sclerosis; Spasm
- Focus Therapeutic Use
- Acronyms Flex201
- Sponsors Flex Pharma
- 19 Jan 2017 Prortocol amendment as per Australian New Zealand Clinical Trials Registry;washout period extended,enrollment ctiteria added,and patient number changed to 80
- 19 Jan 2017 Planned number of patients changed from 50 to 80.
- 28 Jun 2016 Status changed from not yet recruiting to recruiting.